Synaura, as the sole Chinese domestic raw material company, participated in the formulation and publication of the Scientific Consensus on Human Milk Oligosaccharides (HMOs) (hereinafter referred to as the Consensus). The company attended the Consensus launch event organised by the Chinese Institute of Food Science and Technology in Beijing on 18 July 2023. Professor Chen Junshi, Academician of the Chinese Academy of Engineering and Chief Advisor to the National Food Safety Risk Assessment Centre; Professor Shao Wei, Executive Vice President of the Chinese Institute of Food Science and Technology; Professor Luo Yunbo, Honorary Vice President of the Chinese Institute of Food Science and Technology and Professor at Beijing Technology and Business University; Professor Zhang Yumei, Tenured Professor at Peking University School of Public Health; Professor Zhang Lanwei, Director of the Functional Dairy Products and Probiotics Engineering Laboratory at Ocean University of China; Professor Liu Long, Dean of the School of Biological Engineering at Jiangnan University; Researcher Zhang Jianbo, Director of the Third Standards Division at the National Food Safety Risk Assessment Centre; Researcher Huang Jian from the National Institute for Nutrition and Health at the Chinese Center for Disease Control and Prevention; alongside drafting working group experts, corporate representatives, and media delegates attended the launch event. This briefing provides a detailed analysis of human milk oligosaccharides (HMOs), covering their current safety status, nutritional necessity, production techniques and applications, alongside an overview of regulatory frameworks governing HMOs in selected countries and regions. In her address, Ms Shao Wei, Executive Vice President of the Chinese Institute of Food Science and Technology, stated that while HMOs have been approved for sale in most countries worldwide, they remain unlicensed in China. Given that infant formula primarily uses animal milk—particularly cow's milk—as its raw material, and cow's milk contains negligible levels of human milk oligosaccharides, it is imperative to fortify infant formula with HMOs. To advance the application and industrial development of human milk oligosaccharides (HMOs) in China, thereby expediting consumer benefits, it is imperative to continually provide high-quality products and foster high-quality industry development. Guided by this consensus, the Chinese Institute of Food Science and Technology convened experts and industry representatives from diverse fields including food science, medicine, clinical nutrition, and regulatory standards. They conducted a systematic scientific review covering HMO fundamental research, safety and functionality, industrialisation status, and domestic and international regulatory frameworks. Following extensive and in-depth discussions, this Consensus Document was formulated. It is hoped that this Consensus will provide scientific support for the approval of human milk oligosaccharides, advance their application and research, and offer authoritative guidance for consumers to develop a scientifically informed understanding of these compounds. Regarding the future development of human milk oligosaccharides, Executive Vice Chairperson Shao Wei proposed three recommendations: Accelerate the approval process for human milk oligosaccharides Strengthen research and application of human milk oligosaccharides Simultaneously advance the popularisation of human milk oligosaccharide science As human milk oligosaccharides have yet to be approved for market release in China, consumers lack sufficient scientific understanding of them. It is hoped that the publication of this consensus will serve as a starting point to promote the application and innovative development of human milk oligosaccharides in China, thereby genuinely benefiting the wider consumer population. Towards the conclusion of the conference, Academician Chen Junshi chaired a media interaction session where journalists from multiple outlets posed questions regarding the safety, applications, and future development of human milk oligosaccharides. Professors Luo Yunbo, Zhang Yumei, and Zhang Lanwei, alongside Researcher Huang Jian, addressed media concerns on selecting products containing HMOs, the safety profile of HMOs, industrial applications, and China's regulatory approval framework. Future Synaura Biotech pledges to keep pace with industry advancements, proactively embracing the mission of fostering local innovation in intelligent biomanufacturing. We are committed to independent innovation and industrial implementation, empowering China to leapfrog ahead in the Fourth Industrial Revolution and guiding the sector towards steady progress.